Browsing Tag
obesity treatment
39 posts
Cirius Therapeutics shows 0602K and tirzepatide combo preserves muscle and burns fat in obesity and type 2 diabetes
Cirius Therapeutics unveils new ADA 2025 data showing MPC inhibitor 0602K significantly improves muscle and fat metabolism when combined with tirzepatide.
June 22, 2025
Novo Nordisk advances amycretin to phase 3 after early data show weight loss of up to 24% in obesity trials
Novo Nordisk moves amycretin to phase 3 after early trials show up to 24% weight loss. See what makes this dual-receptor drug a next-gen obesity contender.
June 21, 2025
Novo Nordisk’s high-dose Wegovy delivers 21% weight loss in STEP UP Phase 3 trial results
Novo Nordisk’s high-dose Wegovy led to 21% weight loss in a Phase 3 trial. Learn what the STEP UP data means for obesity care and future regulatory plans.
June 21, 2025
Can Lilly’s flat $499/month Zepbound pricing reshape obesity drug access in the U.S.?
Lilly expands Zepbound access via LillyDirect, offering all FDA-approved doses for $499/month. Explore the implications for patients and the GLP-1 drug market.
June 17, 2025
Roche partners with Zealand Pharma to advance petrelintide in obesity treatment
Roche has entered into an exclusive collaboration and licensing agreement with Zealand Pharma to develop and commercialise petrelintide…
March 18, 2025
AbbVie to develop amylin analog for obesity treatment in $350m licensing deal with Gubra
AbbVie has taken a significant step into obesity treatment through a licensing agreement with Denmark-based Gubra, a company…
March 3, 2025
More affordable Zepbound? Lilly’s new pricing plan shakes up obesity treatment
Eli Lilly and Company (Lilly) has introduced new single-dose vials of Zepbound (tirzepatide), expanding treatment options for self-pay…
February 26, 2025
Novo Nordisk’s Amycretin outshines rivals in weight-loss drug trials
Novo Nordisk has achieved a critical milestone in the fight against obesity, reporting highly promising results from an…
January 27, 2025
Novo Nordisk’s semaglutide 7.2 mg sets new standard in obesity treatment with STEP UP trial results
Novo Nordisk, a leader in chronic disease care, has unveiled compelling results from its STEP UP obesity trial.…
January 17, 2025
Novo Nordisk’s CagriSema demonstrates superior weight loss results in REDEFINE 1 trial
Novo Nordisk A/S has unveiled significant findings from its REDEFINE 1 trial, marking a major advancement in the…
December 22, 2024